Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis.

ABSTRACT: Myasthenia gravis can be efficiently treated with rituximab but there is no consensus regarding administration and dose schedules in this indication. No marker has yet been described to predict the clinical relapse of patients. Our objective was to identify the B cell subpopulations predicting clinical relapse in patients suffering from generalized myasthenia gravis and treated with rituximab. Clinical and biological data of 34 patients followed between 2016 and 2019 were prospectively collected every 3 months. Using multiparameter flow cytometry, we assessed the percentage in leucocytes of lymphocytes and several B cell subpopulations measured in residual disease conditions. CD19+ were also measured in non-residual disease conditions. Clinical examinations were performed by neurologists u

SUBMITTER: Ruetsch-Chelli C 

PROVIDER: S-EPMC8423951 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature